PGCM
FLNA

Prescott Group Capital Management’s Filana Therapeutics FLNA Stock Holding History

Prescott Group Capital Management’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-13,186
Closed -$187K – 195
2014
Q4 		$187K Buy
+13,186
New +$228K 0.03% 216

Other funds holding FLNA

First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Prescott Group Capital Management's FLNA Position: Q1 2015 in Review

Prescott Group Capital Management sold out of Filana Therapeutics (FLNA) in Q1 2015, closing a stake of 13,186 shares — an estimated $187K sold.

Prescott Group Capital Management first reported a position in FLNA in Q4 2014 and held it in 1 quarter. The position peaked at $187K in Q4 2014. 64 funds tracked by Wall St. Rank hold FLNA as of Q1 2015.

  • Prescott Group Capital Management reported no remaining Filana Therapeutics position as of Q1 2015 after selling out during the quarter.
  • Prescott Group Capital Management sold 13,186 Filana Therapeutics shares in Q1 2015, an estimated $187K.
  • Prescott Group Capital Management first reported a position in Filana Therapeutics in Q4 2014 and held it in 1 quarter.
  • Prescott Group Capital Management's Filana Therapeutics position peaked at $187K in Q4 2014.
  • 64 funds tracked by Wall St. Rank held Filana Therapeutics as of Q1 2015.

Based on Prescott Group Capital Management's 13F filing for Q1 2015, filed 27 Apr 2015.